Clinical trial · Interventional
The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping
The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer
NCT04868747CI-TRIAL-00063192withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to financial problem
Summary
Brief summary (as posted)
To investigate the effect of perioperative lidocaine infusion on the neutrophil extracellular trapping after minimally invasive surgery for stomach cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine | Drug | — | UNRESOLVED |
| normal saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- study group
- description
- The study group receives the intravenous 1% lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h during surgery and 1.0 mg/kg/h until 24 hours after surgery (Max.\<120 mg/h).
- interventionNames
- Drug: Lidocaine
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- The control group receives intravenous normal saline 0.15 ml/kg bolus followed by 0.15 ml/kg/h during surgery and 0.1 mg/kg/h until 24 hours after surgery.
- interventionNames
- Drug: normal saline
Primary outcomes (1)
- measure
- serum concentration of NET(neutrophil extracellular trapping)-related biomarker
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of stomach cancer * ASA class I-III * no metastatic disease Exclusion Criteria: * hepatic, renal disease * chronic inflammatory disease, eg. rheumatoid arthritis * steroid or anti-inflammatory drug medication * allergies to study drugs * neuropsychiatric disease * refusal of participation * breast feeding or pregnancy * weight \< 40 kg
References
Publications (0)
Data not yet available
No reference posted for this study.